LENSAR (LNSR) Competitors $8.32 -0.25 (-2.92%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LNSR vs. CVRX, NPCE, SMTI, LUNG, DRTS, ELMD, ZYXI, INGN, NYXH, and RCELShould you be buying LENSAR stock or one of its competitors? The main competitors of LENSAR include CVRx (CVRX), NeuroPace (NPCE), Sanara MedTech (SMTI), Pulmonx (LUNG), Alpha Tau Medical (DRTS), Electromed (ELMD), Zynex (ZYXI), Inogen (INGN), Nyxoah (NYXH), and AVITA Medical (RCEL). These companies are all part of the "medical equipment" industry. LENSAR vs. CVRx NeuroPace Sanara MedTech Pulmonx Alpha Tau Medical Electromed Zynex Inogen Nyxoah AVITA Medical CVRx (NASDAQ:CVRX) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership. Does the media refer more to CVRX or LNSR? In the previous week, CVRx had 20 more articles in the media than LENSAR. MarketBeat recorded 20 mentions for CVRx and 0 mentions for LENSAR. CVRx's average media sentiment score of 0.64 beat LENSAR's score of 0.00 indicating that CVRx is being referred to more favorably in the media. Company Overall Sentiment CVRx Positive LENSAR Neutral Do analysts rate CVRX or LNSR? CVRx presently has a consensus price target of $17.00, suggesting a potential downside of 3.52%. LENSAR has a consensus price target of $8.00, suggesting a potential downside of 3.85%. Given CVRx's higher possible upside, research analysts clearly believe CVRx is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CVRx 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86LENSAR 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CVRX or LNSR more profitable? LENSAR has a net margin of -34.03% compared to CVRx's net margin of -123.75%. LENSAR's return on equity of -49.02% beat CVRx's return on equity.Company Net Margins Return on Equity Return on Assets CVRx-123.75% -89.06% -52.56% LENSAR -34.03%-49.02%-21.12% Does the MarketBeat Community prefer CVRX or LNSR? CVRx received 26 more outperform votes than LENSAR when rated by MarketBeat users. Likewise, 72.09% of users gave CVRx an outperform vote while only 38.46% of users gave LENSAR an outperform vote. CompanyUnderperformOutperformCVRxOutperform Votes3172.09% Underperform Votes1227.91% LENSAROutperform Votes538.46% Underperform Votes861.54% Which has more volatility & risk, CVRX or LNSR? CVRx has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Which has higher earnings and valuation, CVRX or LNSR? LENSAR has higher revenue and earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCVRx$39.29M10.88-$41.20M-$2.70-6.53LENSAR$42.16M2.29-$14.38M-$1.46-5.70 Do institutionals & insiders have more ownership in CVRX or LNSR? 75.3% of CVRx shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 18.9% of CVRx shares are held by company insiders. Comparatively, 66.0% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryCVRx and LENSAR tied by winning 9 of the 18 factors compared between the two stocks. Get LENSAR News Delivered to You Automatically Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNSR vs. The Competition Export to ExcelMetricLENSARSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.60M$4.71B$5.21B$9.14BDividend YieldN/A47.30%5.13%4.02%P/E Ratio-5.7026.2989.4217.36Price / Sales2.2958.291,240.0477.11Price / CashN/A50.1443.7535.97Price / Book2.807.795.314.79Net Income-$14.38M$13.87M$122.54M$225.00M7 Day Performance8.62%2.85%1.42%2.37%1 Month Performance8.05%10.48%2.51%4.40%1 Year Performance133.05%32.32%25.29%20.10% LENSAR Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNSRLENSAR0.8331 of 5 stars$8.32-2.9%$8.00-3.8%+133.1%$96.60M$42.16M-5.70110CVRXCVRx1.9407 of 5 stars$15.04+6.1%$16.67+10.8%-33.6%$364.93M$47.26M-5.57160News CoveragePositive NewsNPCENeuroPace3.5325 of 5 stars$12.11+1.4%$15.00+23.9%-16.2%$361.46M$76.45M-12.11170SMTISanara MedTech2.087 of 5 stars$32.46+0.7%$47.00+44.8%-11.5%$283.73M$78.06M-32.7960LUNGPulmonx2.2144 of 5 stars$7.05+4.3%$12.75+80.9%-51.9%$278.39M$79.30M-4.80250Positive NewsDRTSAlpha Tau Medical2.4878 of 5 stars$3.70+14.6%$8.00+116.2%+28.2%$258.72MN/A-8.6080Short Interest ↑ELMDElectromedN/A$30.47+2.4%N/A+216.9%$257.72M$57.06M42.32160News CoveragePositive NewsZYXIZynex3.233 of 5 stars$7.77-0.8%$14.00+80.2%-24.9%$247.44M$193.67M51.801,100Positive NewsINGNInogen3.3558 of 5 stars$10.33+8.2%$7.00-32.2%+95.7%$246.04M$331.52M-4.591,030Short Interest ↓Positive NewsNYXHNyxoah2.7765 of 5 stars$9.33+0.9%$17.00+82.2%+142.2%$232.69M$5.08M-4.99110News CoveragePositive NewsRCELAVITA Medical1.9536 of 5 stars$8.82-3.5%$18.00+104.1%-37.8%$231.24M$60.04M-3.96130 Related Companies and Tools Related Companies CVRx Competitors NeuroPace Competitors Sanara MedTech Competitors Pulmonx Competitors Alpha Tau Medical Competitors Electromed Competitors Zynex Competitors Inogen Competitors Nyxoah Competitors AVITA Medical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LNSR) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.